How AI is reshaping antibody discovery and optimization workflows
In silico antibody discovery and optimization: How computational tools are reshaping the workflow AI-enabled and ML-powered methods are enabling faster identification and engineering of high-quality therapeutic antibody leads The field of antibody discovery is experiencing a transformative shift through the integration of cutting-edge artificial intelligence (AI) and machine learning (ML) technologies. Traditional methods of antibody […]
Discovery of highly-specific TCR mimic antibodies to WT1
Navigating high homology: Discovery of TCR mimic antibodies with greater specificity to Wilms tumor 1 antigen The development of TCR mimic (TCRm) antibodies (or TCR-like antibodies) offers a promising new approach for cancer immunotherapy but identifying TCRm antibody candidates with optimal specificity and low off-target effects can be challenging. Here, we look at an antibody […]
Discovering Antibodies in Months
Access the webinar recording Thanks for your interest in our recent antibody discovery webinar, Discovering Antibodies in Months: New Advances in HT-SPR, Single-Cell BCR-Seq and RNA-Seq. Alloy Head of Global Bioanalytics Dr. Lucy Liu presented on our workflow that improve the speed and quality of the antibody discovery process. Please fill out your contact information, and […]
Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
Targeting GPCRs With DeepImmune™
Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Webinar Overview: Discover how to access previously untapped sources of high-affinity antibodies. In this presentation, Dr. Joe de Rutte from Partillion Bioscience and Dr. Dilip Challa from Alloy Therapeutics discuss how breakthrough technology can help: Access Plasma Cell Diversity: Discover how nanovial technology enables screening of plasma cells from ATX-GK transgenic mice harboring fully human […]
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation
Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation. BOSTON, Mass. – September 20, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and […]
High Efficiency CAR Discovery Screening
Chimeric antigen receptor cell therapy (CAR-T, CAR-NK, etc.) is a promising therapeutic modality, but functional screening is a bottleneck for traditional two-step CAR-T discovery process of antibody binder discovery and CAR-T functional engineering. In this webinar, scientists at Alloy showcase their unique CAR discovery workflow that incorporates human antibody identification and characterization, mRNA-based CAR construct […]
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]